OptimizeRx Corporation Earnings Recaps
Q2 2026
Aug 14, 2026
Shares surged 26.9% following Q2 results that beat revenue and adjusted EBITDA expectations, driven by ongoing margin expansion and strong commercial momentum in AI-enabled offerings and platform innovation.
Key takeaways
- Q2 revenue reached $20.5 million with adjusted EBITDA of $4.9 million, both surpassing consensus estimates.
- Despite some revenue declines from a few large customers transitioning away from lower-margin services, growth was evident across the broader business.
- AI-enabled software subscriptions grew 25% year-over-year, underscoring a successful shift toward recurring revenue models.
- Three new product launches, including integration with DeepIntent’s DSP and the AI-powered natural language audience builder, bolster the company’s competitive position.
- Reiteration of full-year 2026 guidance ($95–100 million revenue; $21–25 million adjusted EBITDA) reflects confidence despite some near-term revenue variability.
Q3 2025
Nov 7, 2025
OptimizeRx reported a robust Q3 2025 with revenues of $26.1 million, reflecting a 22% year-over-year growth, and an adjusted EBITDA of $5.1 million, exceeding expectations.
Key takeaways
- Revenue guidance for FY 2025 has been raised to $105-$109 million, with adjusted EBITDA now expected between $16-$19 million.
- Average revenue from the top 5 customers has grown beyond $11 million, demonstrating strong client relationships and engagement.
- The company continues to reduce its debt, paying down an additional $2 million, and does not anticipate needing to access equity capital markets in the near future.
- Gross margin improved to 67.2%, driven by a favorable product and channel mix, alongside disciplined cost management efforts.
- Initial guidance for FY 2026 indicates revenue of $118-$124 million and adjusted EBITDA of $19-$22 million, signaling confidence in future growth.